Key result
(-)-Epicatechin dose-dependently lowers systolic BP and improves renal function in preclinical kidney disease.
Why the study?
Chronic kidney disease is associated with high cardiovascular risk and progression driven by hypertension, endothelial dysfunction, and oxidative stress, requiring new therapeutic approaches.
Does (-)-epicatechin improve progression markers of chronic renal damage in a 5/6 nephrectomy mouse model?
Does (-)-epicatechin improve progression markers of chronic renal damage in a 5/6 nephrectomy mouse model?
In a mouse model of chronic kidney disease, (-)-epicatechin reduced blood pressure, improved renal function markers, and preserved renal tissue morphology.
Aims To evaluate the effects of (-)-epicatechin (Epi) in the progression of kidney damage. Material and methods We assessed the effects of Epi [0.01–20 mg/kg of body weight/day] during 14 days, in a 5/6 nephrectomy model in mice. Key findings Nephrectomy-induced systolic arterial hypertension was significantly reduced in a dose dependent manner with Epi treatment. Increased serum creatinine and urea were reduced almost to normal values. The concentration of tetrahydrobiopterin (BH4), used as subrogate of endothelial dysfunction, decreased in nephrectomyzed animals, Epi treatment increased BH4 levels almost reaching normal values. The expression of angiotensin II receptor (AT 1 -R) and NADPH oxidase-4 (NOX-4) and 3-nitrotyrosine levels increased with nephrectomy and were reduced with Epi treatment. Renal tissue morphology in the remaining tissue was conserved with Epi treatment in a dose dependent manner. Significance. Chronic kidney disease (CKD) is an independent cardiovascular risk factor associated with a mortality rate 10 to 20 times higher than that of the general population. High blood pressure, endothelial dysfunction and oxidative stress are important factors determining kidney damage progression. Findings of this study indicate that Epi is able to counteract the deleterious effects of subtotal nephrectomy and the structural and functional changes in the remnant kidney tissue, decreasing the progression of CKD. These results warrant the possibility of implement clinical trials to limit the progression of CKD in humans.
No takes yet. Share an insight, caveat, or question.
Montes-Rivera et al. (2019) studied Chronic renal damage. (-)-epicatechin (Epi) was evaluated on Progression of kidney damage (systolic arterial hypertension, serum creatinine, urea, BH4, AT1-R, NOX-4, 3-nitrotyrosine, renal tissue morphology). Treatment with (-)-epicatechin (0.01-20 mg/kg/day) for 14 days dose-dependently reduced systolic arterial hypertension and improved renal function and morphology in a mouse 5/6 nephrectomy model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: